ReviewFrontiers in pharmacology2021
Intestinal Mucosal Barrier Is Regulated by Intestinal Tract Neuro-Immune Interplay.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Virobiome-mediated regulation of microbiota-gut-brain axis signaling and neuroimmune homeostasis.Cell communication and signaling : CCS · 2026Review
- Auricular Vagus Nerve Stimulation in Inflammatory Bowel Disease: Mechanistic Insights and Biomarker-Based Evaluation of Therapeutic Response.International journal of molecular sciences · 2026Review
- Application of Probiotics and Postbiotics in Neurological Disorders.Current pharmaceutical biotechnology · 2026Review
- Neuroimmune Interactions in Inflammatory Skin and Intestinal Diseases.Journal of inflammation research · 2026Review
- Gastrointestinal endoscopy for physiological assessment in functional gastrointestinal disorders: a perspective.Frontiers in medicine · 2026Article
- A study on the role of Tai Chi training in improving type 2 diabetes mellitus.Frontiers in public health · 2026Article
- Targeting the Gut-Brain Axis Through Insulin-like Growth Factors: Therapeutic Implications and Future Directions.Journal of molecular neuroscience : MN · 2025Review
- Flavonoids fromFoods (Basel, Switzerland) · 2025Article
- NMN reverses D-galactose-induced neurodegeneration and enhances the intestinal barrier of mice by activating the Sirt1 pathway.Frontiers in pharmacology · 2025Article
- The potential link between inflammatory bowel disease and male erectile dysfunction: mechanistic insights and novel therapeutic perspectives.Frontiers in immunology · 2025Review
- Caffeic Acid Alleviates Chronic Sleep Deprivation-Induced Intestinal Damage by Inhibiting the IMD Pathway inJournal of inflammation research · 2025Article
- Cell-derived biomimetic drug delivery system for inflammatory bowel disease therapy.Materials today. Bio · 2024Review
- Examining the complex Interplay between gut microbiota abundance and short-chain fatty acid production in amyotrophic lateral sclerosis patients shortly after onset of disease.Scientific reports · 2024Article
- Interplay between Microbiota and γδ T Cells: Insights into Immune Homeostasis and Neuro-Immune Interactions.International journal of molecular sciences · 2024Review
- The effect of nerve cells on the intestinal barrier function and the influence of human milk oligosaccharides (hMOs) on the intestinal neuro-epithelial crosstalk.Current research in food science · 2024Article
- Depletion of muscularis macrophages ameliorates inflammation-driven dysmotility in murine colitis model.Scientific reports · 2023Article
- Article
- A Novel Perspective on Neuronal Control of Anatomical Patterning, Remodeling, and Maintenance.International journal of molecular sciences · 2023Review
- Targeting inflammasome pathway by polyphenols as a strategy for pancreatitis, gastrointestinal and liver diseases management: an updated review.Frontiers in nutrition · 2023Review
- Sympathetic Innervation Modulates Mucosal Immune Homeostasis and Epithelial Host Defense.Cells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease, irritable bowel syndrome and severe central nervous system injury can lead to intestinal mucosal barrier damage, which can cause endotoxin/enterobacteria translocation to induce infection and is closely related to the progression of metabolic diseases, cardiovascular and cerebrovascular diseases, tumors and other diseases. Hence, repairing the intestinal barrier represents a potential therapeutic target for many diseases. Enteral afferent nerves, efferent nerves and the intrinsic enteric nervous system (ENS) play key roles in regulating intestinal physiological homeostasis and coping with acute stress. Furthermore, innervation actively regulates immunity and induces inherent and adaptive immune responses through complex processes, such as secreting neurotransmitters or hormones and regulating their corresponding receptors. In addition, intestinal microorganisms and their metabolites play a regulatory role in the intestinal mucosal barrier. This paper primarily discusses the interactions between norepinephrine and β-adrenergic receptors, cholinergic anti-inflammatory pathways, nociceptive receptors, complex ENS networks, gut microbes and various immune cells with their secreted cytokines to summarize the key roles in regulating intestinal inflammation and improving mucosal barrier function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.